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The therapeutic paradigm in Alzheimer’s disease (AD) is shifting from symptoms 19 
management towards prevention goals. Secondary prevention requires the identification of 20 
individuals without clinical symptoms of AD, yet “at-risk” of developing Alzheimer’s 21 
dementia in the future, and thus, the use of predictive modeling. 22 
The objective of this study was to review the ethical concerns and social implications 23 
generated by this new approach. 24 
We conducted a systematic literature review in Medline, Embase, PsycInfo, and Scopus, and 25 
complemented it with a gray literature search between March and July 2018. Then we 26 
analyzed data qualitatively using a thematic analysis technique. 27 
We identified thirty-one ethical issues and social concerns corresponding to eight ethical 28 
principles: (i) Respect for autonomy, (ii) Beneficence, (iii) Non-maleficence, (iv) Equality, 29 
Justice and diversity, (v) Identity and stigma, (vi) Privacy, (vii) Accountability, transparency 30 
and professionalism, and (viii) Uncertainty avoidance. Much of the literature sees the 31 
discovery of disease-modifying treatment as a necessary and sufficient condition to justify 32 
AD risk assessment, overlooking future challenges in providing equitable access to it, 33 
establishing long-term treatment outcomes and social consequences of this approach, e.g. 34 
medicalization. The ethical/social issues associated specifically with predictive models, such 35 
as the adequate predictive power and reliability, infrastructural requirements, data privacy, 36 
potential for personalized medicine in AD and limiting access to future AD treatment based 37 
on risk stratification, were covered scarcely. 38 
Therefore, the ethical discussion needs to advance to reflect recent scientific developments 39 
and guide clinical practice now and in the future, so that necessary safeguards are 40 
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Alzheimer’s Disease (AD) is the cause of 70% of all dementias [1], characterized by the 47 
combination of cognitive, behavioral and functional decline, leading to loss of autonomy. AD 48 
represents a significant public health challenge worldwide. The disease course is understood 49 
as a continuum from the preclinical stage without cognitive symptoms, to Mild Cognitive 50 
Impairment due to AD (MCI) and then dementia due to AD. Knowledge of the 51 
pathophysiology of AD has improved over the last decade, bringing about a deeper (albeit not 52 
conclusive) knowledge of genetic predisposition, identification of biomarkers (e.g., amyloid-53 
β (Aβ) plaques in the brain or tau protein in cerebrospinal fluid) as well as new insights about 54 
their interaction with protective or disease-promoting factors [2–4]. In turn, these genetic, 55 
molecular and environmental risk factors, or the subjective perception of declining cognitive 56 
capacities have been found useful to identify cognitively unimpaired individuals at higher 57 
risk of developing MCI due to AD and later on dementia due to AD [5–7]. Consequently, the 58 
therapeutic paradigm of AD has recently shifted from symptoms management in individuals 59 
diagnosed with MCI or dementia based on their clinical symptoms, to secondary prevention 60 
goals targeting “at-risk” individuals and aiming at modifying the natural course of the 61 
disease. Contributing to this shift are recent drug development programs testing earlier in 62 
disease course compounds that previously failed in clinical trials (RCTs) on participants with 63 
MCI or dementia [8],
 in a hope that they can be efficacious if used earlier in the disease 64 
course, even at preclinical stages of AD [9]. Recent claims that aducanumab, an anti-Aβ 65 
immunotherapy, improves cognition in patients with MCI or mild AD, lends some credibility 66 
to this approach. 67 
In the research setting, participants are enrolled to the clinical trials testing preventive 68 
treatments only if they have elevated AD biomarkers or genetic predispositions (cf. 69 




have a fairly low probability of developing AD in the future. Predictive modeling, i.e., the use 71 
of patients’ data and of statistical models to estimate the likelihood of future outcomes, based 72 
on historical data [10], can help to produce a more accurate assessment of the probability of 73 
conversion from being cognitively unimpaired to MCI or dementia within a certain 74 
timeframe. Data used in such models: individuals’ demographics (e.g. age, sex, level of 75 
education), genetic markers (e.g. APOE4), and comorbidities (e.g. cardiovascular diseases) as 76 
well as longitudinally captured brain imagining metrics (e.g. PET scans to establish Aβ 77 
status) and results of cognitive tests can, can typically be found in clinical registries from 78 
memory clinics. Even though as of today the applications of such models are mostly in 79 
research settings, some clinics offer AD biomarker testing to their patients, followed by non-80 
pharmaceutical intervention, e.g. lifestyle changes, cognitive rehabilitation, etc. In a future, 81 
aspirational scenario, predictive modeling could be applied in combination with a preventive 82 
treatment (currently not available), e.g. to identify patients with high risk of developing 83 
clinical symptoms of AD or patients likely to benefit most from the therapy. 84 
 A predictive model could also be developed based on minimal sets of demographic and 85 
clinical information. Such model could be used in a hypothetical scenario for broad (e.g. 86 
population) screening aiming to crudely sift out from a general population individuals who 87 
might have an increased risk of developing AD in the future, so that these individuals could 88 
undergo further investigation using brain imagining, and other biomarker or genetic analyses.  89 
Such new therapeutic paradigm in AD raises numerous ethical concerns and may have 90 
various social implications. Some of these concerns are typical for preventive medicine in 91 
general, yet at the core of the problem is AD’s specific setting – the need to intervene years or 92 
even decades before the onset of any cognitive, behavioral or functional decline [11] without 93 
a certainty that an individual would ever develop clinical symptoms of AD, while the long-94 




long-term consequences of future preventive AD treatment is due to the long natural history 96 
of AD which makes it impossible to evaluate in clinical trials, currently lasting up to 5 years 97 
in AD, all its clinical consequences. Likewise, the clinical trials will not be sufficient to fully 98 
appreciate the long-term societal consequences of preventive intervention, critical also from 99 
the perspective of drug reimbursement, due to the limited length of follow-up, narrow choice 100 
of endpoints, and stringent inclusion criteria. This is another context where predictive 101 
modeling can and likely will be applied to remedy the knowledge gaps, e.g. through models 102 
bridging between strictly clinical trial endpoints (like neuropsychological assessment) and 103 
societally relevant outcomes (like institutionalization). Yet, predictive modeling and the entire 104 
discipline of predictive medicine enabled by the technological and computational 105 
developments in the recent decades raises further ethical concerns and social implications. 106 
A lively scientific debate about the ethical aspects of recruitment of pre-symptomatic 107 
individuals to clinical trials and observational studies has already been taking place in the 108 
recent years [12]. As AD prevention efforts will need to target a large number of people in 109 
order to be impactful this debate will intensify. As soon as an efficacious preventive 110 
treatment is developed, a sense of urgency will arise to provide Disease-Modifying Treatment 111 
(DMT) [13] to aging populations, to prevent public health crisis and the associated soaring 112 
burden of care. 113 
OBJECTIVES 114 
The objective of the present study was to systematically review and discuss the ethical 115 
concerns and social implications raised by the use of predictive modeling in the setting of 116 
secondary prevention of AD. We focused on the types of arguments with particular relevance 117 
for current and future, anticipated or aspirational clinical practice. 118 




with an intervention aiming to prevent or delay the onset of clinical symptoms  [14,15]; and 120 
predictive modeling as the use of data from multiple individual subjects in statistical models 121 
to identify the likelihood of future outcomes—including patient-level outcomes—based on 122 
historical data [10]. 123 
Our specific research questions were identified through a preliminary, targeted literature 124 
search [16] and include the following: 125 
1. What are the ethical concerns and social implications associated with 126 
a. Selection of individuals for assessment of the risk of developing clinical 127 
symptoms of AD via predictive modeling, from a general population or 128 
population with known risk factors? 129 
b. The disclosure of individual’s risk of developing AD clinical symptoms 130 
assessed using predictive modeling? 131 
c. Preconditioning of access to AD preventive treatment, based on the predictive 132 
modeling, e.g. by selecting patients at high risk (in a future, aspirational 133 
scenario)? 134 
d. Assessment of the benefit-to-risk from AD preventive treatment administered 135 
at the preclinical stage, made using predictive modeling? 136 
2. What are the broader, population-level ethical concerns and social implications of 137 
using predictive modeling tools in the setting of secondary AD prevention? 138 
METHODS 139 
Definitions 140 
Whenever we refer to MCI or dementia we mean MCI due to AD, and dementia due to AD.  141 
The term “at risk of AD” refers here to being cognitively unimpaired but having an elevated 142 




was established (e.g. using genetic or biomarker analysis, or using an aggregation of risk 144 
factors from multiple data domains). “Preclinical AD” refers to cognitively unimpaired 145 
individuals with established AD biomarker. Whenever we use the term “preventive 146 
treatment” we mean the future, aspirational drug targeting AD, used before AD clinical 147 
symptoms are developed. 148 
Protocol development 149 
The study protocol was prepared according to the reporting guidelines of the Preferred 150 
Reporting Items for Systematic Reviews and Meta-Analysis for Protocols 2015 (PRISMA-P) 151 
[17,18], registered with the PROSPERO international prospective register of systematic 152 
reviews (registration number CRD42018092205) on April 6th, 2018 and published [19]. The 153 
completed PRISMA-P checklist is provided in the Supplementary table 1. 154 
Search methods 155 
A comprehensive, systematic literature search was conducted between May and July 2018. 156 
The literature was retrieved from the Embase/Medline Daily, Scopus and PsycINFO between 157 
28th and 31st of May, 2018 including coverage from 2007 until the search date. Additionally, 158 
a gray literature search was performed within pre-defined websites of relevant non-159 
governmental organizations and professional associations, and using a generic Google search 160 
engine, where the first 10 pages of results were reviewed for potentially relevant entries. The 161 
full electronic search strategy is provided in the Supplementary table 2. 162 
Study selection 163 
The systematic literature search followed the SPICE framework (Setting, Perspective, 164 
Intervention, Comparison, Evaluation) [20]. Included in the analysis were studies discussing 165 
ethical concerns or social implications, both from individual and societal perspective, both of 166 




demographics, genetic data, imaging data, cerebrospinal fluid examination, etc.) as a 168 
component of secondary AD prevention. Studies were included if discussing preclinical AD, 169 
including those with subjective memory complaint/cognitive impairment but without MCI 170 
diagnosis. We included studies reporting on the results of research on humans (basic, clinical, 171 
social, reviews/meta-analyses, observational, randomized controlled trials), including 172 
conference abstracts, editorials, commentaries, guidelines, discussion and position papers, 173 
books and book chapters published in English, French or German from the year 2007 174 
onwards. The choice of this time span reflects the fact that secondary prevention is a recent 175 
therapeutic strategy against AD. Details of the study selection criteria are presented in Table 176 
1. 177 
[Table 1 about here] 178 
The retrieved abstracts were independently assessed by two reviewers and disagreements 179 
were adjudicated by a third reviewer. Reviewers had a possibility to exclude not eligible 180 
studies based on a review of the full-text versions prior to the extraction process. 181 
Data extraction 182 
Data were extracted from the eligible studies by single reviewers. The extraction was 183 
performed using a semi-structured extraction sheet where textual content extracted by all 184 
reviewers was uploaded in real time into an online spreadsheet for further qualitative data 185 
analysis. Text fragments were extracted according to the pre-specified research questions, 186 
aforementioned in the introduction of this paper, with a checklist of ethical concerns or social 187 
implications known to appear in this context. This checklist was derived from a seed of four 188 
studies [21–24] selected for this purpose by one reviewer and a bioethicist independent to this 189 
study. Lastly, for each of the research questions, open-ended text boxes were added to allow 190 




in the structured checklist. The extraction sheet development process is described in more 192 
detail in the systematic review protocol [19]. 193 
Data analysis 194 
Extracted data were analyzed qualitatively using a thematic analysis approach [25,26] defined 195 
as "a method for identifying, analyzing, and reporting patterns (themes) within data which 196 
minimally organizes and describes (your) data set in (rich) detail but also interprets various 197 
aspects of the research topic” [25]. The theme is defined as “a repeated pattern of meaning, 198 
capturing something important about the data in relation to the research question, and 199 
representing some level of patterned response or meaning within the data set” [25]. In 200 
characterizing salient ethical arguments the focus was on the claims being made and the 201 
arguments supporting them, not on quantitative assessment of the number of times a given 202 
claim appears in the literature. Therefore, the frequency was not treated as a measure of 203 
importance. The research questions of this study defined the highest level themes which were 204 
further broken down into the lowest level of ethical and social considerations. In order to 205 
make sure that complex ethical arguments were understood in context, full-text papers were 206 
revisited during the iterative analytic process and reviewers were encouraged to use memos 207 
liberally during extraction and analysis. Both pre-specified and newly identified ethical and 208 
social considerations were then classified as either ethical concern or social implication, and 209 
grouped into themes. The connections and interdependencies between the themes were 210 
investigated. While the analysis relied upon self-nomination of ethical relevance by a 211 
reviewer, the grouping into ethical themes was matched with the additional mapping of the 212 
ethical principles establishing the perceived ethical relevance of each theme to the issue of 213 
predictive modeling. These principles were drawn from background literature in medical and 214 





Risk of bias 217 
One potential bias to a literature review is to treat what is most commonly reported as the 218 
most important. This bias is mitigated by the qualitative character of the present study, 219 
striving to understand a wide spectrum of the ethical and social concerns and disregarding 220 
their frequency in the literature. However, a potential inter-reviewer heterogeneity when 221 
different reviewers appraise manuscripts and documents in a different manner could result in 222 
some ethical arguments being missed or misinterpreted. To mitigate this bias, the team of 223 
reviewers participated in a face-to-face workshop on April 28th, 2018 in Barcelona, during 224 
which the research objective, strategy, and extraction tools were thoroughly discussed and 225 
reviewed when needed. Further to that, the reviewers come from different backgrounds, 226 
including sociologist, clinical psychiatrist, psychologist, market access professionals 227 
specializing in AD, a pharmacist and market access professional, and a 228 
mathematician/statistical modeler. Finally, the results could be affected by a publication bias. 229 
RESULTS 230 
Study selection 231 
The systematic literature search yielded in total 180 citations, 154 in bibliographic databases 232 
including Embase/Medline, PsycInfo, and SCOPUS and 26 through a manual search 233 
conducted in Google. After removal of duplicates, 152 abstracts were screened against the 234 
inclusion criteria and 92 were excluded at this stage. After full text screening 12 additional 235 
publications were excluded. Reasons for exclusions are listed in Figure 1. In total, 48 236 
publications were retained. 237 




Study characteristics 239 
Of the forty-eight retained publications, thirty-two were journal articles with the majority of 240 
them coming either from medicine/gerontology (thirteen out of thirty-two) or 241 
interdisciplinary domain (twelve out of thirty-two). Four articles came from psychiatry or 242 
neuroscience field, and the remaining were published in social science or ethics journals. 243 
Seven further publications were either conference abstracts, proceedings or presentations, six 244 
were reports and three were books or book chapters.  245 
Results of the individual studies 246 
Table 2 summarizes the ethical concerns and social implication identified in the literature, 247 
structured along the research questions. Table 3 shows the matching of ethical concerns and 248 
social implication to one or more ethical principles. 249 
[Table 2 about here] 250 
[Table 3 about here] 251 
Selection of a population for risk assessment via predictive modeling 252 
Who should have their AD risk assessed is one of the critical questions in the ethical debate 253 
around AD prevention. One approach could be population screening, e.g. screening 254 
everybody after a certain age, yet such an intervention might lead to “turning everyone into 255 
patients” [12,21,23,24,28–33] and excessive operational burden for healthcare systems. 256 
Alternatively, model-based, precise assessment of AD risk could be made only among those 257 
with known risk factors for AD. While these two approaches belong to the classic arsenal of 258 
public health prevention, another unique concept identified in the literature was “screening 259 
whoever wants to be screened” [34] yet not without  a question whether access to screening 260 
should be limited to individuals assessed beforehand as emotionally capable of eventually 261 




“screening before screening” [12,21,28,31,35–37]. Voluntary access to screening can be 263 
defended on pragmatic grounds by the fact that commercial genetic testing for AD is already 264 
available and will most likely come into large demand as soon as DMT is developed [34,38]. 265 
Policymakers must ensure that healthcare and social systems are prepared in terms of 266 
implementation of laws safeguarding a growing number of patients, their data and their 267 
interests and that professional and social policies are put in place to not only treat but also 268 
advise and educate them [28,31,35,39–45]. 269 
Several ethical themes speak against assessing the risk of AD. The most prominent of them is 270 
the current lack of DMT rendering risk assessment not actionable [21,22,46–271 
54,24,28,32,33,35,37,40,43] and potentially even harmful, e.g. when side effects of invasive 272 
biomarker testing are considered [30,41] or the threat of overdiagnosis [4,12,33,37,40–273 
43,54,21,23,24,28–32] and competing risks are taken into account [37,40,42,54]. The issue of 274 
competing risks is particularly valid in the AD setting, where at-risk or preclinical stage 275 
might span decades and where the elderly patient population might be prone to other age-276 
related diseases. Further reservations against AD risk testing are: lack of adequate tests with 277 
sufficient predictive power to provide a trustworthy risk assessment [21,30,33,38,42,54], lack 278 
of social consensus as to what predictive power could be considered sufficient [21,38], and 279 
uncertainty, whether the presence of Aβ plaques is causally associated with AD [37,40,42]. 280 
The latter argument is not relevant, though, in the predictive modeling setting, where co-281 
occurrence can be sufficient to predict future outcomes. 282 
Disclosure of individual risk assessed using predictive modeling 283 
Considerations around disclosure practices do not differ substantially depending on whether 284 
they are based on genetic, biomarker or imaging assessment, with an exception of the specific 285 
discussion on familial, early onset AD. Particularly relevant in this context of people with 286 




patient’s uncertainty of their AD risk [37,39,53] and possibilities for future planning 288 
[4,12,57,58,30,31,35,37,43,48,55,56]. Ethical considerations depend in turn to a large extent 289 
upon whether the disclosure is made in research setting in the absence of DMT vs. in 290 
hypothetical clinical setting where DMT is available. In the latter case, there might even be 291 
an ethical obligation for disclosure [4,31]. The governing ethical principle here is a postulate 292 
that the diagnosis should provide a patient with a benefit that overweighs the risks. Some 293 
papers, however, consider benefit much broader than access to treatment, pointing rather to 294 
the need of establishing whether a risk assessment brings clinically meaningful information 295 
[4,31], considering patient’s individual situation, including the availability of support 296 
[39,40,59] and their level of willingness to know their risk status, as it might mediate the 297 
level of benefit from the diagnosis [4,35,40,58]. 298 
On the other hand, major groups of arguments against disclosure address psychological 299 
harms associated with the remaining, post-testing uncertainty of the positive risk assessment 300 
until symptoms occur [12,30,36,37,40,53] and even without certainty whether they will 301 
occur, given the possibility of a false-positive diagnosis [38,53]. The ethical and social 302 
ramifications of a false-negative diagnosis are not specifically discussed in the literature. A 303 
very prominent theme in the literature stresses the risk of discrimination of people with high 304 
risk of developing AD symptoms within the workplace, healthcare system and society overall 305 
[21,22,58,28,39,40,44,45,49,55,57] which might lead to their distress [4,37,40,43,49,56] and 306 
potentially even objective, realistic limitation in how they perform in their daily life [12,30]. 307 
AD risk assessment can bring about negative consequences not only to the patient, but to his 308 
or her relatives and significant others, as they might become anxious about their own risk 309 
[39,40] or about the upcoming challenges of taking the role of a supporter or carer [39,40]. 310 
Accurately communicating AD risk assessment to patients is considered challenging given 311 




level of understanding of the disease and the uncertainty of preclinical risk assessment, level 313 
of agency and support, individual predispositions for depression; as well as unique statistical 314 
properties of particular methods which are used to make such a prognosis[38,58]. 315 
Treatment: preconditioning access to treatment and assessing benefit from it using 316 
predictive modeling 317 
The relationship between the access to screening and to the treatment is reciprocal, meaning 318 
that the recommendation for screening is often preconditioned on the availability of DMT 319 
[28,30] and that access to treatment can be conditional on the results of the screening. It is 320 
clear that some form of qualification for treatment access other than age is needed once 321 
preventive treatment is available [38] in order to avoid overmedicating the whole population 322 
and unsustainable costs, but no answers are given as the topic is addressed only very sparsely 323 
in the literature. In this context, the question emerges whether it is ethical to restrict the 324 
access to DMT based on the results of model-based assessment of AD risk, given that for 325 
some proportion of patients they might be false [30].  Subsequent considerations, that the 326 
model could also biased, unreliable or otherwise faulty are not being discussed in the AD 327 
prevention literature. We elaborate more on these topics in discussion. 328 
Instead, the main themes that emerge around the topic of treatment and conditioning of 329 
treatment access is equity and distributive justice, understood mostly as equal access of 330 
individuals at risk of AD to general health services as opposed to being discriminated against 331 
by insurers [22,28,55] and balance in the amount of stakeholders’ attention and resources 332 
dedicated to preclinical AD, vs. dementia due to AD [12,24,30,36] vs. other healthcare needs 333 
[12,30,39,53,54]. In addition to that, the burden incurred to the healthcare systems by 334 




Even once access to potential, future DMT is granted, an important uncertainty remains 336 
regarding the rationale for prolonged treatment in the preventive settings. There is a concern 337 
that possible side effects of preventive treatment [4,22,36], coupled with intensive and 338 
potentially invasive monitoring might in some cases overweigh the benefits 339 
[21,22,30,34,49,60]. Therefore future patients need to be informed about the benefits and 340 
risks of treatment to be able to weight these factors according to their own personal values 341 
and make an informed decision [28,59]. 342 
The concern regarding the benefit of future preventive treatment is amplified by uncertainty, 343 
as to whether a treatment benefit observed in clinical trials will represent the true effect in a 344 
real-world population of patients. This could happen if real-world patients are different, for 345 
example, more diverse than those recruited to the clinical trials based on stringent inclusion 346 
criteria [30]. A concern is raised also regarding whether the outcomes meaningful to patients 347 
will be adequately captured or at least informed by the clinical trials, which are typically 348 
limited in their time of follow-up [30,54]. This short time horizon of clinical trials is being 349 
seen as critical for the inability to make an accurate assessment of preventive treatment’s 350 
real-world outcomes and cost-effectiveness [22,32,33,36,38,49,54,61]. Cost-effectiveness of 351 
both diagnostic tests and the preventive treatment is seen as a requirement for offering them 352 
to patients [55,61,62] but the literature diverges when it comes to opinions whether future AD 353 
treatment will be cost-effective or not. Some papers present claims that future early treatment 354 
will be superior to current symptomatic treatments, and that it will offset costs of healthcare 355 
and institutionalization. In such scenario, there is even an ethical obligation to make this 356 
treatment available to patients [22,40]. Opposite views dominate though due to a concern that 357 
the direct cost of innovative preventive treatment and of associated clinical monitoring will 358 
be large [22,30,31,36,38], while offsets will occur in the social care, rather than healthcare 359 




there is a caveat in that modeling is highly complex and the results depend on modeling 361 
assumptions. Therefore model inputs must be clearly defined and transparently 362 
communicated [38]. The literature does not provide answers yet as to what predictive power 363 
of a model used for preclinical testing would be desired and acceptable. 364 
 365 
Broader social implications of using predictive models for AD prevention, and other 366 
social issues 367 
The existing literature recognizes the need to facilitate development and adoption of effective 368 
AD strategies, given the major public health importance of AD. Public-private partnerships 369 
are often mentioned as an example of such strategies [12,30,31,33,36,61]. A sense of urgency 370 
can be seen regarding the need to regulate access to AD risk assessment which is already 371 
available to some patients through direct-to-consumer testing [40,56,58,61]. 372 
The future preventive approach to AD is expected to put a strain on the healthcare and social 373 
system, creating a demand for more intensive interaction between patient and doctor, 374 
assistance to people with preclinical AD to plan for and monitor emerging disabilities 375 
[22,31,63], and to provide care arrangements for them [31,38]. The existing literature 376 
recognizes the imminent tensions which might arise from this and calls for a priority setting 377 
process with public participation [28] and postulates that all patients in need have access to 378 
diagnosis and treatment, so as to prevent further health inequalities [22]. 379 
Further important ethical questions raised in the context of AD prevention using predictive 380 
modeling is how far medicine should go in terms of treating risk factors or risk status 381 
[12,31,56], and to what extent it should become “clinical-actuarial rather than clinical-382 
pathologic” [31]. The rise of so-called “desktop medicine”, where patients learn about their 383 




technological challenges, e.g. to develop an optimal governance model for patient’s data, 385 
assure their privacy and accountability of those handling them [36,44]. Not to be ignored are 386 
also high technical and infrastructural requirements for data gathering and managing, 387 
particularly for population-level AD screening [22,30,36,38] and the need to adapt 388 
professional practices, social policies and legal infrastructure need to evolve to accommodate 389 
this paradigm shift in AD treatment [31]. 390 
Last but not least, it is worth noting that the topic of AD secondary prevention is discussed 391 
mostly from a perspective of high income countries, leaving out unanswered questions such 392 
as how these topics are being perceived outside the Global North [36,40] and whether low 393 
and middle-income countries possess means and infrastructure to also benefit from early AD 394 
diagnosis, management, and treatment [38]. The expectation is that the transnational gap will 395 
only increase once DMT become available [38]. 396 
DISCUSSION 397 
This review investigated the ethical and social considerations which arise in the secondary 398 
AD prevention setting where predictive models can be used particularly for assessment of the 399 
risk of AD clinical symptoms in cognitively unimpaired individuals or prediction of long-400 
term AD outcomes with and without treatment. The themes drawn from the reviewed 401 
literature reflect current academic discussion of those aspects that bear ethical or broader 402 
societal relevance, i.e. can be understood as statements regarding ‘right’ and ‘wrong’, the 403 
‘goodness’ of practice or phenomenon, or competing normative interests and values among 404 
relevant stakeholders. 405 
Much—although not all [38]—of the current literature is centered around the DMT being a 406 
necessary and sufficient condition for ethical risk assessment and disclosure. We did not 407 




cognition-based intervention, physical exercise) that may be effective in the early stages of 409 
AD [64], while better tolerated than pharmacological options. We argue that the discovery of 410 
DMT while resolving many critical issues related to AD prevention, creates others. 411 
The first one is that the availability of a DMT will not automatically translate into 412 
accessibility, challenging the principle of equity and distributive justice. One can expect that 413 
such innovative treatment will be costly, at least during the first years after launch when it 414 
will be protected by a patent, and so will the battery of tests needed to select the target 415 
preclinical population. This means, that a large proportion of patients who could benefit from 416 
preventive treatment, insured in middle- and lower-income countries, might not have access 417 
to it and in high income countries paying for AD preventive treatment will off-set other 418 
healthcare or public needs.. 419 
The other issue introduced by the discovery of DMT is that despite overall efficacy 420 
demonstrated in a clinical trial, some aspects of drug’s benefit-to-risk will remain unclear. 421 
This is because the long-term consequences of using this treatment will not be clear from the 422 
RCT alone, and because it will not be known whether all eligible patients will benefit from 423 
the treatment, and if not, whether some patients will be harmed. This issue, though, rooted in 424 
the ethical principle of non-maleficence, can be mitigated with further post-marketing 425 
studies, monitoring long-term consequences of such treatment and further scientific progress 426 
in the identification of potential responders, possibly leading one day to a stratified or even 427 
personalized medicine approach in AD. On the other hand, a rush in introducing a DMT into 428 
clinical practice in the preventive setting might severely limit our ability to adequately and 429 
comparatively monitor the long-term progression of AD and the long-term benefit to risk of 430 




Finally, a side effect of the attempt to alter the AD trajectory and postpone, or even prevent 432 
cognitive decline and disability, is its contribution to creating a new patient population of 433 
“worried well” from individuals who otherwise considered themselves healthy, to the 434 
medicalization of private life, and to transforming medicine into an “actuarial” science and 435 
practice. These changes are not trivial.  Positive AD risk assessment can impact self-436 
perceptions or self-identity. Similar effects can occur for relatives, family members and 437 
friends who discover information about their susceptibility to AD, or learn about the 438 
susceptibility of a relative, resulting in (planned) modification of familial, social, or caring 439 
roles. AD risk assessment may likewise result in discrimination comparable to that facing 440 
symptomatic AD dementia patients, family members, and carers. People at risk of AD (i.e. 441 
who may or may not develop AD dementia at some point in the future) may, for example, 442 
also be exposed to attitudes, practices or procedures which potentially devalue or 443 
discriminate against them (e.g. monitoring their ability to manage finances or to drive already 444 
before the symptoms occur, perhaps even as a part of a well-intended policy). This is while 445 
patients often fear loss of agency more than they fear death [43], perhaps because of the 446 
social stigma associated with AD, overemphasizing the most advanced stages of AD, as 447 
opposed to providing support allowing people affected by AD to function in various domains 448 
in life as long as possible. 449 
Another finding from this review is that although ethical issues in AD secondary prevention 450 
are discussed abundantly in the literature, specific issues related to modeling used to predict 451 
AD risk are not scrutinized. One instance of this is the existing literature around disclosure 452 
practices which seems to be deeply anchored in the paradigm of a single risk factor, primarily 453 
genetic, or to a lesser extent, biomarker-related. Assessment of personal risk estimated using 454 
advanced predictive methods, combining a number of patient characteristics as described 455 




scarce and incomplete. For example, the uncertainty around the prediction of AD is typically 457 
understood in the literature as the probability of making a false-positive diagnosis and 458 
therefore raises the problem of misclassification by a predictive algorithm. The reviewed 459 
literature is likewise missing any specific considerations regarding the clinically and socially 460 
acceptable levels of precision and reliability of the models which could be used in the AD 461 
secondary preventive setting and therefore, it is currently not possible to derive from the 462 
literature any indication about the qualities of a predictive algorithm that would justify its use 463 
in populations known to be at risk, and in the general population. 464 
 Also specific sources of uncertainty and biases leading to misclassification are not being 465 
discussed. Such biases can be purely technical (e.g. low granularity of data for prediction 466 
affecting the precision of prediction) but can also be rooted in social attitudes and practices, 467 
either pre-existing at the time when a predictive model is being developed or emerging during 468 
and through the use of this model [65]. As a hypothetical example, a person whose relative 469 
have AD might be more likely referred to a specialized memory clinic compared to a person 470 
without this risk factor (preexisting bias) resulting in data from memory clinics 471 
overrepresenting this type of future patients (technical bias). In effect, a model developed on 472 
such data could produce more accurate predictions for this group of patients, compared to 473 
others (external generalizability). Such a model subsequently used in a clinical practice could 474 
then contribute to the underrepresented patients receiving suboptimal care or even to being 475 
discriminated against. The clinical use of such a complex, multivariate predictive model 476 
would pose more challenges. For example, the same level of risk can be derived from such a 477 
model for two patients based on completely different sets of characteristics, and therefore, be 478 
associated with a different degree of uncertainty. This feature might make the AD prediction 479 
based on such a model more demanding to communicate to both the patient and the treating 480 




it would even be very difficult to trace back the reasons why a certain prediction was made. 482 
In additional to that, commercially developed models will likely be patented and not open for 483 
public scrutiny. Therefore, any potential harm caused by biased prediction would be difficult 484 
to discover, posing a risk that a faulty model would shape the clinical practice for an 485 
extended period of time and leading to a dispute who is to be held accountable for the fault of 486 
a self-learning predictive model [66]. In this new context data governance needs to be 487 
reassessed, starting from fundamental issues such as informed consent (To what extent is it 488 
possible, given the complexity and unknown long-term consequences of using predictive 489 
models in routine care?) and data privacy (How to assure that patients will not be de-490 
identified based on a unique set of characteristics used in the multivariate predictive model?), 491 
through ownership (If patients or clinics contributed data to develop a model, who owns the 492 
model?) and accountability (What business model would best strike balance between model 493 
developers rights and profits and public interest?), all the way to very specific consideration 494 
around data sharing for modeling purposes. The latter is a challenge because unlike in the 495 
case of descriptive analytics which can be generated internally within the institution of a data 496 
owner and shared externally, building a predictive model requires multiple iteration of access 497 
to data which can hardly be done without a physical access. 498 
Furthermore, the existing literature on Alzheimer’s Disease barely mentions a possibility that 499 
a predictive model can serve not only as an elective preventive procedure, but also as a basis 500 
for a populational surveillance system, e.g. when connected to an Electronic Medical Record 501 
(EMR) system, and this is despite the growing interest in using EMR for public health 502 
surveillance and case detection [67,68]. In AD setting, patients identified by one predictive 503 
algorithm with high sensitivity and low specificity could be called into a healthcare practice 504 
for an AD risk assessment, using a more specific algorithm, e.g. including biomarkers. 505 




AD secondary prevention. Any extensive use of such advanced models predicting risk of 507 
future AD will have large logistic requirements for data collection, processing and storage.  508 
While these large themes are clearly underrepresented in the current literature on AD, a 509 
discussion around mathematical models used to predict future AD outcomes for the needs of 510 
health technology assessment is emerging. The most straightforward example of such a 511 
model is a health-economic model which will be needed to evaluate the cost-effectiveness of 512 
the preventive AD treatments, once they are developed. It is being recognized that results of 513 
such a model will depend to a large extent on the choice of the modelled outcomes and 514 
assumptions. Therefore, established criteria for such model’s trustworthiness are needed, so 515 
that it could be used for decision making. As part of this effort, a series of studies have been 516 
conducted in the ROADMAP project (Real World Outcomes across the AD Spectrum for 517 
Better Care) [69], focusing on the ethical and social implications of data sharing and 518 
repurposing, priority outcomes for different AD stakeholders and methodologies as well as 519 
input data used in the currently existing health-economic models in AD [70,71]. Reporting 520 
standards have also emerged for both economic evaluations and predictive models (CHEERS 521 
and TRIPOD, respectively) [72,73]. 522 
FUTURE DIRECTIONS 523 
This review uncovered several directions for future research. 524 
The first one would be to supplement the current review conducted in the AD setting, with a 525 
review of literature on the developments in the field of predictive modeling, machine 526 
learning, and precision medicine, which—even if not specific to AD—could provide a 527 
perspective on specific challenges to be expected if predictive models are used in routine 528 
clinical care. Some lessons can also be learned from other specific fields were predictive 529 




others [74]. Such a review could also further explore how the use of predictive models for 531 
preclinical risk assessment can affect access to preventive treatment. For example, whether 532 
risk stratification could lead to unfair exclusion of people who might desire to receive a 533 
preventive AD therapy, but be denied access, if not meeting a certain pre-defined risk 534 
threshold. 535 
The second direction would be to examine the perspectives on secondary AD prevention 536 
from low- and middle-income countries, given that the reviewed literature discussed mostly 537 
the high-income countries perspective. Some of the differences which we expect to see would 538 
be in beliefs about the benefits of risk disclosure and in considerations and realities of limited 539 
access to current and future AD therapies. 540 
Finally, another topic to explore is the possible policy consequences of a large scale AD 541 
prevention. The literature suggests that focus on prevention would divert resources from care 542 
offered to symptomatic AD patients. It is, however, possible that standards of AD care 543 
improve, if large scale AD risk assessment creates an organized group of cognitively 544 
unimpaired people aware of their likely future with AD clinical symptoms and ready to 545 
engage in policy making. 546 
LIMITATIONS 547 
One potential limitation of this study is that it reflects the current status of the ethical 548 
discussion about the ethical aspects of using predictive modeling in AD secondary 549 
prevention. We found that this discussion does not yet follow the most recent medical 550 
developments in the AD field. Similarly, we did not identify articles discussing the benefit-551 
to-risk of non-pharmacological interventions (e.g., cognition-based intervention, physical 552 
exercise) that may be effective in the early stages of AD, while better tolerated than 553 




Another potential limitation stems from the fact that the mapping of ethical themes relies to a 555 
large extent on qualitative interpretation of the reviewers. To mitigate the risk of self-556 
nomination eight principles were used as guidelines to establish the ethical relevance of each 557 
theme. The eight principles are not intended as an ethical framework for predictive modeling, 558 
but rather were used as a reference point to further establish the ethical relevance of the 559 
themes identified in the reviewed studies beyond self-nomination by study authors. 560 
CONCLUSIONS 561 
Based on our understanding of the AD and therapeutic landscape in this indication, we 562 
believe that advanced predictive modeling might become an indispensable element of AD 563 
preclinical prevention. In such scenario, given the numerous ethical concerns associated with 564 
this approach, safeguards need to be implemented. Public health and medical institutions 565 
undertaking AD preventive programs are accountable to the general public and patient 566 
populations whose health and well-being are at stake. Risk-benefit assessments, model 567 
validation, and development of professional practices and norms are necessary to establish 568 
and deliver effective and publicly beneficial screening programs and treatment access plans. 569 
Evidence supporting the implementation of such programs should be shared with relevant 570 
patient populations to support well-informed autonomous decision-making regarding 571 
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Table 1 Criteria for study selection with instructions for reviewers and examples  
 
Included Excluded 
Setting Documents discussing pre-symptomatic/ 
asymptomatic individuals at-risk of AD, 
including those with subjective memory 
complaint/cognitive impairment but 
without MCI diagnosis. 
 
Examples: 
asymptomatic patients with genetic 
predisposition, family history, presence 
of AD biomarkers, abnormal biomarkers, 
treatment prior to onset, cognitively 
intact, cognitively normal, prodromal 
AD (only if understood as asymptomatic, 
when in doubt or not specified/clear --
>include),  
Documents discussing ONLY symptomatic 
stages of AD; documents discussing dementia 




MCI (Mild cognitive impairment) or prodromal 
AD (if defined as encompassing first 
symptoms); cardiovascular dementia, 
alcohol/drug, metabolic/diabetic/insulin 
resistance, Lewy body dementia 
Intervention Documents discussing either the 
predictive modeling method (statistical 
algorithms) or source data (including 
secondary data re-use) as a component of 
secondary AD prevention. 
Secondary prevention is - targeting 
asymptomatic/pre-symptomatic people 
at-risk of AD, preventing disease or 
delaying its onset. 
 
Example of potential data sources for 
predictive modeling: 
Genetic - Presenilins (PSEN-1, PSEN-2), 
APOE4; Imaging - PET scan, MRI; 
Cerebrospinal fluid (CSF); 
Electronic/Medical Health Record; 
Biomarker status (Amyloidosis, 
Amyloid-β, Aβ, tau); Comorbidities; 
Family history of AD 
Documents discussing secondary prevention but 
without any component of predictive modeling 
(neither method, nor data source); documents 
which do not discuss secondary prevention of 
AD (e.g. discuss tertiary prevention targeting 
individuals with MCI and later). 
 
Tertiary prevention is slowing down the 
progression once symptoms/MCI or AD 
dementia occurs. 
Evaluation Ethical discussion or commentary on 
secondary prevention of AD supported by 
predictive modeling (as indicated in the 
abstract) is present. 
Ethical discussion or commentary on secondary 
prevention of AD supported by predictive 
modeling (as indicated in the abstract) is absent. 
Publication 
date 
2007-2018 All prior to 2007 




Study type Primary and secondary research on 
humans (clinical, social, observational, 
RCTs, reviews, meta-analyses), 
abstracts, posters, editorials, 
commentaries, discussion and position 
papers and other media, conference 
abstracts, books and book chapters, 
reports  














Selection of a population for risk assessment via predictive modeling 
1. AD risk assessment is not ethical without sound treatment options, 
therefore existence of a disease-modifying treatment is a pre-requisite 




2. Patients participating in screening might be misdiagnosed, given that 
adequate diagnostic tests for preclinical AD are currently not available. 
False positive diagnosis is of particular ethical concern. 
EC [21,30,33,42,43,5
4] 
3. There is no social consensus regarding the sufficient predictive value of 
a set of tests, or other test’s characteristics, that would give social 
legitimization to population screening. 
SI [21,38] 
4. AD risk assessment will lead to over-diagnosis and potential harm… EC [4,12,33,37,40–
42,54,21,23,24,28
–32] 
 a. …because of the slow disease progression/competing risks.  [36,54] 
 b. …because of unknown validity of biomarkers in the clinical practice 
(e.g. lack of evidence that Aβ plaques are causal for the disease). 
 [37,40,42] 
 c. …because diagnostic tests can have side effects.  [30,41] 
5. Population screening for preclinical AD will transform healthy 
individuals into preclinical AD patients. 
SI [12,21,23,24,28–
33] 
6. It is not ethical to withhold a possibility to undergo AD risk assessment 
from people who are interested in learning about their genetic and 
overall risk level. 
EC [34] 
7. Access to AD risk assessment should be limited to people with good 




8. Certain safeguards are needed before offering access to AD risk 
assessment, such as… 
 [28,31,35,39–45] 
 a. …provision of appropriate information and education. EC [28,31,35,39–44] 
 b. …receipt of informed consent. EC [28,31] 
 c. ….assessment of impact of the AD risk assessment on individual 
and/or family level (need for individualization of the clinical practice). 
EC [39,40] 
 d. …defining a standardized process, incl. developing 
diagnostic/predictive modeling guidelines (need for standardization of 
the clinical practice). 
EC, SI [31,35,39,41,45] 
 e. …adaptation of professional practices, definition of social policies 
and laws to prevent stigmatization of individuals at risk of AD. 
EC, SI [31,39,40,42–44] 
Disclosure of individual risk assessed using predictive modeling 
9. Certain pre-requisites are needed for ethical disclosure of individual  
AD risk, such as… 
 [4,31,35,39,40,58,
59] 
 a. …establishing that the risk assessment provides meaningful clinical 





 b. …being able to offer a disease-modifying treatment to patient (in 
which case arises an obligation to disclose the risk). 
EC [58] 
 c. …receiving an explicit request from the patients, since patient’s 
autonomy is decisive for whether a disclosure should be made or not. 
Further on, patient’s willingness to know might mediate the benefit 
from the AD risk assessment. 
EC [4,35,40,58] 
 d. …establishing a positive individual benefit-risk, taking into account 
patient/carer characteristics, family sphere and external environment. 
EC, SI [39,40,59] 
10. Disclosure of risk status brings about positive consequences for the 





 a. …potential alleviation of anxiety associated with uncertainty of their 
AD risk. 
EC [37,39,53] 
 b. …creating a possibility for future planning (will, power of attorney, 




11. Disclosure of risk status brings about negative consequences for the 





 a. …potential induction of anxiety associated with living for years 
without a certainty of diagnosis, until symptoms occur. 
EC [12,30,36,37,40,5
3] 
 b. …potential false-positive diagnosis, causing people to live for years 
with a threat of a non-existent disease. 
EC [38,53] 
 c. …potential overburdening and overmedicating of people with high 
AD risk. 
EC [30,58] 




 e. …potential depression, distress or suicidal attempts among 
individuals with a high AD risk. 
EC [4,37,40,43,49,56
] 
 f. ...potential objective limitation of people’s performance due to 
stereotyping based on a high AD risk. 
EC, SI [12,30] 
12. Disclosure of risk status brings about negative consequences for the 
family of individuals undergoing screening, such as… 
 [39,40,53] 
 a. …anxiety and uncertainty among relatives and significant others, 
who empathize with the individual with high AD risk or who might be 
overburdened with care responsibilities. 
EC [39,40] 
 b. …anxiety among the relatives, who become aware of their own 
individual risk (risk of familial AD). 
EC [40,53] 
13. There is a risk of miscommunication and therefore misinformation 
while disclosing the risk status to individuals, given the complexity of 




 a. …patients’ heterogeneous characteristics and predispositions.  [28,39,53] 
 b. …characteristics of the specific method or test used to assess the 
risk status. 
 [38,58] 
Treatment and preconditioning of treatment access based on predictive modeling 
14. Preventive AD treatment raises concerns from the perspective 






 a. …diverting resources from current symptomatic AD patients. EC [12,24,30,36] 
 b. …diverting resources from other health needs which might be more 
immediate than future Alzheimer’s dementia. 
EC [12,30,54] 
 c. …potential weakening of the health system, due to the fact that 
insurers will not be able to act upon client’s AD risk status or will not 
be at all informed about the elevated risk in their clients (in certain 
health-care settings). 
SI [39,53] 
15. Early treatment for preclinical AD raises concerns from the perspective 
of equity, such as… 
EC [22,30,38] 
 a. …concern that it is not ethical to restrict access to treatment based 
on age (assuming a scenario, in which people above some threshold 
of age are preventively treated for AD). 
EC [38] 
 b. …concern that it is not ethical to restrict treatment access based on 
risk assessment, because it might be false (assuming a scenario, in 
which only people with high risk are preventively treated for AD). 
EC [30] 
16. People with high risk of AD might face restriction in access to non-AD 
related health care services (e.g. transplant, health insurance). 
EC [22,28,55] 
17. Both preventive treatment and diagnostic tests needs to demonstrate 
cost-effectiveness, before they can be offered to patients. 
EC, SI [55,61,62] 
18. In absence of DMT, the value of an AD risk assessment is limited, as it 
merely extends the time spent as a patient, awaiting treatment or 
symptoms. 
EC [28,30] 
Assessment of the benefit from treatment based on predictive modeling 




 a. ...possibility of adverse events due to treatment, which might 
overweigh the benefit. 
EC [4,22,36] 
 b. …potentially large impact of the cost of preventive treatment on 
payer’s/insurer’s budget. 
SI [4] 
 c. …adverse consequences of repeated monitoring of disease 
progression, and repeated testing, which might be invasive, time 
consuming and expensive. 
EC [21,22,30,34,48,4
9,60] 
20. Decision to undergo preventive treatment should be based on 
individual’s personal benefit-to-risk assessment, according to their 
personal values, but adequate knowledge information about treatment 
might not be available. 
EC [28,59] 
21. There is uncertainty as to whether treatment benefit observed in clinical 
trials will translate to the real world setting of usual care, because… 
EC [30,54] 
 a. …there is no consensus around the endpoints/outcomes relevant in 
real world setting, and about their sensitivity. 
 [30,54] 
 b. …time of follow-up in clinical trials is insufficient to make 




 c. …there are inherent differences between patient populations 
typically enrolled in the clinical trial and real world patients. 
 [30] 
22. The possibility to make an accurate benefit-to-risk assessment is 
hampered by other unknown factors, such as… 
  
 a. …unknown time horizon until the exact consequences of preventive 







23. There is an ethical obligation to offer preventive treatment on the 
grounds of its superior cost-effectiveness, comparing to symptomatic 
AD treatments. Claims of superior cost-effectiveness are based upon 
assumptions that… 
EC [22,40] 
 a. …there will be a large offset of societal burden due to 
avoiding/delaying institutionalization once preventive treatment is 
used. 
SI [22] 
 b. …there will be a significant offset of overall health costs once 
preventive treatment is used. 
SI [40] 
24. There are concerns about whether the preventive treatment, once 
available, will be cost-effective, because 
SI [22,30,31,36,38,4
0] 
 a. …costs of innovative, disease-modifying preventive treatment will 
be substantially higher than the cost of symptomatic treatment. 
Huge budget impact of preventive treatment is expected. 
SI [38] 
 b. …offset of societal burden will occur in a different sector that the 
one which pays for treatment. 
SI [30,38] 
 c. …the societal burden associated with AD prevention (e.g. specialists 
visits, imaging) will be large. 
SI [22,30,31,36,38] 
25. When modeling is used to alleviate challenges in value assessment, 
there is a caveat in that modeling is highly complex and the results 
depend on modeling assumptions. Therefore, modeling might also be 
misguiding. 
EC [38] 
26. Trustworthiness of predictive and health-economic models increases 
when input data to the model are clearly defined. 
EC [38] 
Broader social implications of using predictive models for AD prevention, and other social issues 
27. Broader implications for medicine and health-care include…  [12,22,31,38,56,6
3]  
 a. …increasing relevance of “desktop medicine”, with patients 
learning about their medical condition not based on their symptoms, 
but based on test results. This poses a question, how far to extend 
treatment of risk factors. 
SI [12,31,56] 
 b. …increasing relevance of risk-based, clinical-actuarial rather than 
clinical-pathologic medicine. 
SI [31] 
 c. …creating a demand for more intensive interaction between patient 
and doctor and for assistance for people with high risk of AD to plan 
for and monitor emerging disabilities. 
SI [22,31,63] 
 d. …creating a demand for new, multisectoral care arrangement for 
people with high risk of AD. 
SI [31,38] 
28. Broader implication for society include…   
 a. …the need to facilitate development and adoption of effective AD 
strategies, given the major public health importance of AD and 




 b. …the need to facilitate or regulate access to AD risk assessment, 
given that such practices are already present (clinical practice precedes 
the policy). 
SI [40,56,58,61] 
 c. …the need for priority setting process to address distributive justice 
issues and public engagement into shaping the science. 
SI [22,28] 
29. An appreciation of cultural differences which might influence attitudes 





30. An appreciation of the transnational gap in access to diagnosis and 
treatment is needed. This gap is expected to increase once disease-
modifying treatment is developed. 
SI [38] 
31. An appreciation of technological challenges is needed. Such challenges 
might include: 
  
 a. …the need to ensure privacy of patient’s data and accountability of 
those handling them and potential disputes over optimal governance 
model. 
SI [36,44] 
 b. …potential disputes over optimal governance model. SI [36] 
 c. …high technological and infrastructural requirements for data 
gathering and managing, particularly for population-level AD 
screening. 
SI [22,30,36,38] 
* References are nested, meaning that a reference for a sub-theme populates the reference to the 





Table 3. Mapping of ethical themes to underlying ethical principles 
Ethical principle Definition Relevant ethical themes 
Respect for autonomy Individuals must be treated as 
autonomous agents capable of deciding 
whether to participate in a proposed 
intervention. 
6, 8a, 8b, 9c, 10a, 10b, 20, 27a 
Beneficence Medical interventions should maximize 
possible benefits to the affected 
population. 
1, 8a, 9a, 9b, 9d, 10a, 10b, 14b, 18, 21b, 
21c, 23a, 24a, 24c, 28a 
Non-maleficence Medical interventions should minimize 
possible harms to the affected 
population. 
2, 4a, 4b, 4c, 7, 11a, 11b, 11c, 11e, 12a, 
12b, 16, 19a, 19b, 19c, 22a, 25 
Equality, justice and 
diversity 
The risks and benefits of a proposed 
intervention should be fairly distributed 
across affected stakeholders. 
3, 5, 8c, 11c, 11d, 14a, 14b, 14c, 15a, 
15b, 16, 17, 19d, 19f, 23a, 23b, 24a, 
24b, 24c, 27c, 27d, 28a, 28b, 28c, 29, 
30 
Identity and stigma Patients should not be exposed to the 
risk of being discredited and 
discriminated against. 
5, 8c, 8e, 11b, 11c, 11d, 11f, 12b, 18, 
27a, 27c 
Privacy Information entrusted by patients should 
be safeguarded from inappropriate use. 




Medical professionals and decision 
makers have moral obligations and 
duties to patients and the public, based 
on broader ethical and moral codes, 
standards, and traditions. 
8, 8d, 8e, 9a, 9b, 13b, 21a, 25, 26, 27a, 
27b, 27d, 28c, 30, 31a, 31b 
Uncertainty 
avoidance 
The need for patients to take decisions 
with unpredictable outcomes should be 
minimized. 
1, 9a, 10a, 10b, 11a, 12a, 13a, 13b, 15b, 
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TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both. → Yes, in title 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS). → see section: Objectives and Table 1 
7, 48  
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number. → see section: Protocol development  
7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale. → see section: Study selection 
9 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched. → see section: Search methods and Supplementary file 2 
9, 54  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. → see 





Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis). → see sections: Study selection and Data collection and extraction 
9, 10 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators. → see section: Data collection and extraction 
10 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made. → see section: Data collection and extraction. 
10 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis. → see section: Risk of bias 
11 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means). → Not applicable  
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis. → see section: Data analysis  
10 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies). → see section: Risk of bias 
11 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified. → Not applicable 
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram. → Yes, provided  
49 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations. → see section ‘Study selection’, ‘Data collection and extraction’ and ‘Study characteristics’ where we present we 
present study characteristics. More details on the type of extracted data are included in the study protocol[19]. 
9-11 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). → Not applicable, see 
section: Risk of bias (quality assessment) 
10 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot. → Not applicable  
 
Synthesis of results  21 Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of 
consistency in accordance with the text in the Explanation and Elaboration document. → see section: Results of the individual 
studies. 
12 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15). → Not applicable, see section: Risk of bias 11 






DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
19 
onwards 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
26 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  25, 27 
FUNDING   
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Supplementary file 2: Full electronic search strategy and the retrieved results 
Data source Search terms Element of the 
framework 
Embase/Medlin
e® Daily, Epub 




Date of search: 
2018-05-28 
(Alzheimer$.ti,ab,kw. or Alzheimer Disease/) and (asymptomatic disease?/ or (preclinical or pre-clinical or 
presymptomatic or pre-symptomatic or asymptomatic or (amyloid$ adj2 positiv$) or atrisk or at risk or 




(prediction or (predict$ adj2 (model$ or analytic$)) or prevention or early intervention$ or early treatment$ or 





(ethic$ or ELSI or (social adj3 (issue$ or aspect$ or impact$ or consequence$ or implication$ or effect$ or 
consideration$ or challenge$))).ti,ab,kw. or ethics/ or medical ethics/ or exp research ethics/ or exp bioethics/ or 
Bioethical Issues/ or professional ethics/ or clinical ethics/ or ethics.fs. or Ethical Analysis.sh. or Ethical 








Date of search: 
2018-05-31 
(Alzheimer$.ti,ab. or Alzheimer Disease/) and (asymptomatic disease?/ or (preclinical or pre-clinical or 
presymptomatic or pre-symptomatic or asymptomatic or (amyloid$ adj2 positiv$) or atrisk or at risk or 
(biomarker adj positive) or biomarker based or cognitively normal or cognitively intact or early stage or early 
phase).ti,ab.)   
5338 
(prediction or (predict$ adj2 (model$ or analytic$)) or prevention or early intervention$ or early treatment$ or 
early diagnos#s or early detection).ti,ab. or prediction/ or secondary prevention/ or early diagnosis/ or early 
intervention.sh. 
189810 
(ethic$ or ELSI or (social adj3 (issue$ or aspect$ or impact$ or consequence$ or implication$ or effect$ or 
consideration$ or challenge$))).ti,ab. or ethics/ or medical ethics/ or exp research ethics/ or exp bioethics/ or 
Bioethical Issues/ or professional ethics/ or clinical ethics/ or Ethical Analysis.sh. or Ethical Review/ or 










Date of search: 
2018-05-31 
( TITLE-ABS-KEY (Alzheimer* AND (pre-clinical OR pre-symptomatic OR asymptomatic OR "amyloid* 
positive" OR at-risk OR "biomarker positive" OR "cognitively normal" OR "cognitively intact" OR “biomarker 




( TITLE-ABS-KEY (prediction OR “predict* model*” OR “predict* analytic*” OR prevention OR “early 




( TITLE-ABS-KEY ( "ethic*"  OR  "ELSI"  OR  "social issue*"  OR  "social aspect*"  OR “social impact*” OR 
“social consequence*” OR “social implication*” OR “social consideration*” OR “social challenge*” ) )  
495027 
 







Date of search: 
2018-04-25 
Alzheimer AND (preclinical OR pre-symptomatic) AND (prediction OR prevention OR (early intervention) 
AND (ethic OR ethical) AND (issue OR problem OR concern OR implication) 









part 2 (“Social 
implications”) 
Date of search: 
2018-07-12 
Alzheimer AND (preclinical OR pre-symptomatic) AND (prediction OR prevention OR (early intervention) 
AND ((societal implication) OR (societal issue) OR (societal problem) OR (societal concern)) 










As for Google generic search engine 4 retrieved 
* Alzheimer Europe (https://www.alzheimer-europe.org/), Alzheimer’s Association (https://www.alz.org/), Alzheimer’s Foundation of America (https://alzfdn.org/); 
Alzheimer’s Society, UK (https://www.alzheimers.org.uk/); France Alzheimer (https://www.francealzheimer.org/); The World Health Organization (http://www.who.int/), The 
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